Friday, September 22, 2023
September 10 - 13, 2014; Boston, Massachusetts
ECTRIMS
Smoking Ups Natalizumab Neutralizing Antibodies in MS
ECTRIMS
New Test to Identify PML Risk With Natalizumab in MS
ECTRIMS
Laquinimod in MS: Latest Safety Data 'Reassuring'
ECTRIMS
PML in MS Patients Making Natalizumab-to-Fingolimod Switch
ECTRIMS
Can Diet Affect Multiple Sclerosis?
ECTRIMS
Alemtuzumab for MS: Encouraging 4-Year Data
ECTRIMS
MS Spasticity Responds to Marijuana Extract
ECTRIMS
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS
ECTRIMS
Cognitive Training Improves Thalamic Connectivity in MS
ECTRIMS
Daclizumab in MS: More Detail on Phase 3 Results
ECTRIMS
Generic GA Shows Equivalence on MRI Endpoints in MS
ECTRIMS
First US Study of Mesenchymal Stem Cells in MS
ECTRIMS
Neurologist Survey Shows Consensus on RIS, CIS, MS Treatment
ECTRIMS
Some Children See Well Despite Severe Optic Nerve Damage
ECTRIMS
No Cognitive Disadvantage in Pediatric- vs Adult-Onset MS
ECTRIMS
Retinal Thinning Parallels Neurodegeneration in MS
ECTRIMS
What's Hot at MSBoston 2014?
Medscape Neurology© WebMD, LLC
